October 8, 2026 -- Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, in which Addex holds a 20% equity interest, has completed its Phase 1 clinical studies evaluating NTX-253 and plans to advance NTX-253 into Phase 2 clinical development. NTX-253 is a positive allosteric modulator (PAM) of the

Sept. 30, 2026 -- As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth. Tirzepatide, with annual sales of $36.507 billion in 2025, has become the latest Top Drug, underscoring the industry's momentum and commercial potential. To further advance long-acting and precise weight management, the industry has proposed a combination strategy using GIPR (glucose-dependent insulinotro

- Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. Sept. 29, 2026 -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, today announced that its investigational cell therapy NouvSight001 has received clearance from China's National Medical Products Administration (NMPA) for a Phase I/III clinical trial in patients

-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP -Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month -PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that

SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy - SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS0

Novo will explore the use of Nanexa's PharmaShell technology platform in an effort to reduce the dosing frequency of injectables for the treatment of obesity, type 2 diabetes and other cardiometabolic indications. The deal, disclosed late Thursday by Nanexa, is potentially worth up to €1.165 billion ($1.3 billion). PharmaShell is Nanexa's atomic layer deposition (ALD)-based drug delivery platform, which is designed to enable controlled and sustained release of active pharmaceutical ingredients

Kovina Therapeutics Inc., a biotechnology company developing first-in-class small molecule therapeutics targeting the Human Papillomavirus (HPV) E6 oncoprotein, today announced a $2.3 million Direct-to-Phase II Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI). The two-year award will support IND-enabling development of Kovina’s lead oral small molecule program for HPV-driven cancers. The award follows Kovina’s recent publication in the Proceedings of the N

- 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment. - Steady-state elimination half-life after 28-day treatment in patients was 6.5 days, supporting potential once-weekly oral dosing. - Placebo-adjusted reduction in PASI score reached 65.9% in mild-to-moderate plaque psoriasis patients 15 days after last dose (28th dose), which supports potential once-weekly oral dosin

The FDA on Friday approved AbbVie's Juvmo (tavapadon) to treat adults with Parkinson's disease, according to a listing on the agency's approvals database. The pharma gained the D1/D5 partial agonist through its $8.7-billion takeout of Cerevel Therapeutics, announced in late 2023. However, the centrepiece of that deal, experimental schizophrenia treatment emraclidine, failed in mid-stage testing shortly after the acquisition closed (see – Spotlight On: Three things to watch at AbbVie). Despite

If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more Decision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kg PDUFA target action date of January 30, 2027 September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its